These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 14506016)

  • 21. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.
    Sprandel KA; Schriever CA; Pendland SL; Quinn JP; Gotfried MH; Hackett S; Graham MB; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4597-605. PubMed ID: 15561831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
    Boselli E; Breilh D; Rimmelé T; Djabarouti S; Saux MC; Chassard D; Allaouchiche B
    Crit Care Med; 2005 Jan; 33(1):104-9. PubMed ID: 15644655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.
    Myrianthefs P; Markantonis SL; Vlachos K; Anagnostaki M; Boutzouka E; Panidis D; Baltopoulos G
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3971-6. PubMed ID: 16982782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration.
    Goudah A; Abo El-Sooud K; Shim JH; Shin HC; Abd El-Aty AM
    J Vet Pharmacol Ther; 2008 Oct; 31(5):399-405. PubMed ID: 19000258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
    Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K
    Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.
    Sowinski KM; Lucksiri A; Kays MB; Scott MK; Mueller BA; Hamburger RJ
    Am J Kidney Dis; 2003 Aug; 42(2):342-9. PubMed ID: 12900817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis.
    Scotton PG; Pea F; Giobbia M; Baraldo M; Vaglia A; Furlanut M
    Clin Infect Dis; 2001 Nov; 33(9):e109-11. PubMed ID: 11577376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves.
    Dumka VK
    J Vet Sci; 2007 Dec; 8(4):357-60. PubMed ID: 17993749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
    Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
    Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
    Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
    Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
    Scaglione F; Mouton JW; Mattina R; Fraschini F
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of acute renal failure and ganciclovir on the pharmacodynamics of levofloxacin-induced seizures in rats.
    Ishiwata Y; Son K; Itoga Y; Yasuhara M
    Biol Pharm Bull; 2007 Apr; 30(4):745-50. PubMed ID: 17409514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue pharmacokinetics of levofloxacin in human soft tissue infections.
    Bellmann R; Kuchling G; Dehghanyar P; Zeitlinger M; Minar E; Mayer BX; Müller M; Joukhadar C
    Br J Clin Pharmacol; 2004 May; 57(5):563-8. PubMed ID: 15089808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
    Firsov AA; Zinner SH; Vostrov SN; Portnoy YA; Lubenko IY
    J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.